Ariana Pelosci
Editor at Cancer Network
Assistant Managing Editor @cancernetwrk | University of Delaware ‘21 | Author of Roxy and Velvet’s Big Adventure
Articles
-
4 days ago |
cancernetwork.com | Ariana Pelosci
Elranatamab-bcmm (Elrexfio) plus daratumumab (Darzalex) and lenalidomide (Revlimid; EDR) is safe and manageable for patients with transplant-ineligible multiple myeloma, according to results from the phase 3 MagnetisMM-6 Part 1 dose level G trial (NCT05623020), presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
4 days ago |
cancernetwork.com | Ariana Pelosci
Patients with medium to high locally advanced rectal cancer who received short-course radiotherapy (SCRT) followed by 1 cycle of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and 7 cycles of folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI) had improved activity, according to results from the single-arm phase 2 ShorTrip trial (NCT05253846) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
5 days ago |
onclive.com | Ariana Pelosci
Patients with metastatic breast cancer who had higher pre-treatment HER2 amplicon mRNA (HER2DX) signatures and HER2 proteins (RPPA) who were treated with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) experienced a longer median time to next treatment (TTNT) compared with those with lower signatures and RPPA levels, according to data from a retrospective study presented in a poster during the 2025 ASCO Annual Meeting.
-
5 days ago |
targetedonc.com | Ariana Pelosci
In patients with metastatic castration-resistant prostate cancer (mCRPC), the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) demonstrated clinical activity, while the addition of stereotactic body radiation therapy (SBRT) was well tolerated but did not enhance efficacy. These findings come from the phase 2 CheckPRO trial (NCT05655715) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
5 days ago |
cancernetwork.com | Ariana Pelosci
Patients with metastatic castration-resistant prostate cancer (mCRPC) experienced a response with nivolumab (Opdivo) plus ipilimumab (Yervoy); however, the addition of stereotactic body radiation therapy (SBRT) was found to be safe but did not improve efficacy, according to results from the phase 2 CheckPRO trial (NCT05655715) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 42
- Tweets
- 91
- DMs Open
- No
RT @ginacolumbusonc: Great time in the Big Apple with some of our @OncLive and @CancerNetwrk crew at @gotoPER #NYGU today. Awesome work! 🙌🏻…
It was great speaking with Dr. Taplin today during #NYGU! Excited to see CancerNetwork’s Women in Oncology program come together.
It was a happy #InternationalWomensDay — we sat down with Dr Mary-Ellen Taplin of @DanaFarber to discuss her career in GU oncology! Keep your eye out for a brand new #womeninonc program 👀 #NYGU @gotoPER @APelosci #pcsm https://t.co/uvbciyxGiC
It was great speaking with Dr. Gong about the upcoming @myESMO meeting. He gave a great overview on upcoming presentations, and which will be most impactful in the bladder and gastrointestinal space.
Thank you @CancerNetwrk @APelosci! Always a pleasure catching up on latest GI/GU cancer breakthroughs especially with an exciting @myESMO 2023 fast approaching @CSCancerCenter @CedarsSinaiMed @CedarsSinai